PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for cardiopulmonary diseases. Co.'s primary product candidate, bentracimab, is a reversal agent for the antiplatelet drug ticagrelor. Co. is developing its preclinical product candidate, PB6440, is an aldosterone synthase inhibitor being developed for treatment-resistant hypertension. Co.'s preclinical programs include: Glucagon-like peptide-2, which stimulates growth of intestinal villi, increasing their ability to absorb nutrients and C-type natriuretic peptide, which is a regulator of bone growth and can rescue defects in fibroblast growth factor 3. The PHAS average annual return since 2018 is shown above.
The Average Annual Return on the PHAS average annual return since 2018 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether PHAS average annual return since 2018 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the PHAS average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|